Laurel Wealth Advisors, Inc. Neurocrine Biosciences Inc Transaction History
Laurel Wealth Advisors, Inc.
- $1.01 Billion
- Q4 2022
A detailed history of Laurel Wealth Advisors, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Laurel Wealth Advisors, Inc. holds 1,719 shares of NBIX stock, worth $214,875. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,719
Previous 1,928
10.84%
Holding current value
$214,875
Previous $205,000
-0.0%
% of portfolio
0.02%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding NBIX
# of Institutions
625Shares Held
94.2MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$1.77 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.25 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$644 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$322 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$233 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...